Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has announced that the European Commission approved Apidra, a rapid-acting insulin analog, for the control of hyperglycemia in adolescents and children with diabetes mellitus.
Subscribe to our email newsletter
The approval of Apidra for pediatric use provides children with the option of using Apidra as part of their overall diabetes treatment plan, usually in combination with basal insulin.
The approval is based upon review of a 26-week, Phase III, open-label, active control study of Apidra in comparison with Humalog (both administered premeal) in 572 children and adolescents with type 1 diabetes. Apidra can also be used alone in insulin infusion pump therapy for blood sugar control.
Riccardo Perfetti, senior medical director of diabetes-metabolism franchise at Sanofi-Aventis, said: “Now the rapid-acting insulin analog Apidra will be available to children six years and older with diabetes, and we hope it will offer them an effective treatment of choice for their overall diabetes therapy.”